1Cleland JG, Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am J Cardiol, 1999,83:112D-119D.
2Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J, 1997,133:703-712.
3Gary R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA, 1995,273:1450-1456.
4Cleland JG, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet, 1998,352:19-28.
5Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure: a request for more accurate classification. Eur Heart J, 1996,17:1390-1403.
6Pierpont GL, Cohn JN, Franciosa JA. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest, 1978,73:8-13.
7Jugdutt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular remodeling after canine myocardial infarction. Circulation, 1994,89:2297-2307.
8Packer M, O′Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in servere chronic heart failure. N Engl J Med, 1996,335:1107-1114.
9Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-Heft III. Circulation, 1997,96:856-863.
10The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet, 1999,353:9-13.
4American Heart Association. Heart disease and stroke statistics-2004 update [ M ]. Dallas (TX): American Heart Association, 2004:103.
5Bauters C, Lamblin N, Mc Fadden E P, et al. Influence of diabetes mellitus on heart failure risk and outcome [J]. Cardiovasc Diabetol, 2003 (2) : 1-16.
